Latigo Biotherapeutics

Executive Summary

Latigo Biotherapeutics is a private, Phase 1-stage biotechnology company focused on developing non-opioid pain therapeutics. Founded in 2019 and headquartered in Thousand Oaks, California, the company aims to disrupt pain management by targeting the source of pain before it reaches the central nervous system, thereby avoiding dependence and enabling relief that restores quality of life. By addressing pain at its origin, Latigo's approach differentiates from conventional treatments that dull pain, potentially reducing the risk of addiction and side effects associated with opioids. The company is currently in the early clinical phase, with no disclosed pipeline details or financial data, but its strategic focus on a large unmet need in pain management positions it as a potential key player in the shift away from opioid-based therapies. The company remains private, with no valuation or funding rounds publicly reported, limiting visibility into its financial runway and investor backing. However, the clinical-stage status and specialized niche suggest that upcoming milestones, such as Phase 1 data readouts or regulatory filings, could catalyze interest from partners or investors seeking alternatives in the pain space.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Clinical Data Readout40% success
• Q4 2026Regulatory Filing (IND/CTA) for Second Indication50% success
• TBDPartnership or Licensing Agreement20% success